Cannabis Stock News; APHRIA (TSX VENTURE: $APH)
(OTCQB: $APHQF) AFFIRMS ITS COMMITMENT TO PRODUCING SAFE MEDICAL CANNABIS 100%
FREE OF CHEMICAL PESTICIDES
LEAMINGTON, ONTARIO, March 13, 2017 (Investorideas
Newswire) In light of recent media coverage, Aphria Inc. ("Aphria" or
the "Company") (TSX
Venture: APH) (OTCQB: APHQF) issued the following
statement with respect to its ongoing commitment to providing
pharmaceutical-grade cannabis that is free of chemical pesticides.
Vic Neufeld, Chief Executive Officer of Aphria, said,
“Aphria has always held itself to the highest standards when it comes to the
cultivation and production of medical cannabis. As part of this, we made a
strategic investment in a state-of-the-art greenhouse in Leamington, Ontario,
which enables us to produce medical cannabis that meets our exacting standards
of quality, consistency, and safety.”
“Aphria is committed to product integrity through
every step of the growing process. We make our own fertilizer, which
significantly reduces the risk of unwanted chemicals that can be found in
‘pre-mixed’ fertilizers. Additionally, we do not use chemical pesticides in the
production of medical cannabis; we only use biological controls in the
Leamington greenhouse. To be clear, Aphria has never supported the use of
Myclobutanil.”
“Since Aphria was founded, we have enforced a strict
Quality Management Program that continuously tests for pesticides, including
Myclobutanil. We closely monitor all suppliers to ensure that any products used
meet or exceed the minimum standards set to comply with Health Canada's
regulations. As we noted in December, we support the use of independent
evaluations and testing of medical cannabis as a necessary measure to protect
the safety of Canadians.”
“In all, Aphria has adopted pharmaceutical-grade
quality assurance and quality control processes, many of which are over and
above what is required by Health Canada. We recognize that patients rely on a
safe and high quality product to meet their medical needs and it is critically
important that all products sold through the ACMPR adhere to the strict
guidelines established by Health Canada to ensure that their needs are met.”
“Aphria management has over 35 years of experience in
agriculture and 20 years in the pharmaceutical space, we don’t need to rely on
chemicals because we know how to grow naturally.”
Read this release in full at http://www.investorideas.com/420cannabisinvestorideas/Companies/APH/news/2017/03131Commitment.asp
About Aphria
Aphria Inc., one of Canada’s lowest cost producers,
produces, supplies and sells medical cannabis. Located in Leamington, Ontario,
the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing
for the most natural growing conditions available. We are committed to
providing pharma-grade medical cannabis, superior patient care while balancing
patient economics and returns to shareholders. We are the first public licensed
producer to report positive cash flow from operations and the first to report
positive earnings in consecutive quarters. For more information, visit www.Aphria.com.
For further information please contact:
Mr. Vic Neufeld
Chief Executive Officer
1-844-427-4742
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes
forward-looking statements under applicable securities laws. Any statements
that are contained in this news release that are not statements of historical
fact may be deemed to be forward-looking statements. Forward looking statements
are often identified by terms such as “may”, “should”, “anticipate”, “expect”,
“potential”,“believe”, “intend” or the negative of these terms and similar
expressions. Forward-looking statements in this news release include, but are
not limited to, statements with respect to internal expectations, estimated
margins, timing for completion of final TSX approval, expectations for future
growing capacity and costs, the completion of any capital project or expansions,
any commentary related to the legalization of marijuana and the timing related
thereto, expectations of Health Canada approvals and expectations with respect
to future production costs. Forward-looking statements necessarily involve
known and unknown risks, including, without limitation, risks associated with
general economic conditions; adverse industry events; marketing costs; loss of
markets; future legislative and regulatory developments involving medical
marijuana; inability to access sufficient capital from internal and external
sources, and/or inability to access sufficient capital on favourable terms; the
medical marijuana industry in Canada generally, income tax and regulatory
matters; the ability of Aphria to implement its business strategies;
competition; crop failure; currency and interest rate fluctuations and other
risks.
Readers are cautioned that the foregoing list is not
exhaustive. Readers are further cautioned not to place undue reliance on
forward-looking statements as there can be no assurance that the plans,
intentions or expectations upon which they are placed will occur. Such
information, although considered reasonable by management at the time of
preparation, may prove to be incorrect and actual results may differ materially
from those anticipated.
Forward-looking statements contained in this news
release are expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange (the “Exchange”) nor
its Regulation Services Provider (as that term is defined in the policies of
the Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclosure : Aphria Inc. ("Aphria" or the "Company") (TSX
VENTURE:APH) (OTCQB:APHQF) is a featured company
on the 420 Cannabis Investor
Ideas of 2017 at www.420cannabisinvestorideas.com
Disclaimer/Disclosure:
Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Companies
Featured on the 420 Cannabis Investor Ideas have paid a one-time fee of Up to
$1000 to be featured on the directory
Additional info regarding
BC Residents and global Investors: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
